Table 3.
Distribution of the genotypic, demographic, clinical and laboratory data of the DILI and No-DILI Groups in the studied sample.
| Anti-Tuberculosis Drug-Induced Liver Injury |
|||
|---|---|---|---|
| Presence | Absense | p-value | |
| CYP2E1 | |||
| c1c1/DD | 3/6 | 32/39 | |
|
c1c2/CC or c1c1/DC |
3/6 | 7/39 | 0.09*‡ |
| GST | |||
| NULL T1 | 3/6 | 7/39 | 0.09* |
| NULL M1 | 1/6 | 10/39 | 0.6 |
| ALT (U/L) | 176.3 | 20.7 | <0.001* |
| AST (U/L) | 139.7 | 25.1 | <0.001* |
| T BIL (mg/dL) | 1.18 | 0.58 | <0.003* |
| Age (years) | 46 | 41 | 0.39 |
| Sex | 0.06* | ||
| Male | 2 | 28 | |
| Female | 4 | 11 | |
| Hospitalization Time (days) | 120.7 | 105.6 | 0.59 |
c1 and D: Wild alleles; c2: Variant allele of the Promoter Region; C: Variant allele of the Intronic Region; ALT: Alanine aminotransferase; AST Aspartate aminotransferase; U/L: Unit per liter; T BIL: Total bilirubin; ULN: Upper limit of normal; F: Female sex; M: Male sex; * statistically significant; ‡ Fisher’s exact test.